CytRx,
a biopharmaceutical research and development company that specializes in
oncology treatments, will be hosting a conference call today, Wednesday,
December 11, 2013, at 10:30 am EST to announce a significant company milestone.
The
company will be discussing and answering questions regarding top-line results
of its global Phase 2b clinical trial of its chemotherapeutic drug,
aldoxorubicin, as a first-line treatment for advanced soft tissue sarcomas
(STS) versus the widely used chemotherapeutic agent doxorubicin. At 8:00 am EST
this morning, a press release was made available detailing the results of this
clinical trial.
The
conference call can be accessed by dialing 888-463-4383 (U.S. and Canada) or
706-679-5355 (international callers). A webcast will be accessible in the
Investor Relations section of the company’s website, found at: www.cytrx.com
A
replay of this call and webcast will become available around two hours after
the conference call has officially ended. To access the replay, investors and
attendees are advised to dial 855-859-2056 (U.S. and Canada) or 404-537-3406
(international callers) and to enter the conference ID number: 19821609.
Currently
CytRx is focusing its primary attention on the development of aldoxorubicin,
its improved version of the widely-used chemotherapeutic treatment doxorubicin.
Soft tissue sarcoma is a cancer that appears in muscle, fat, blood vessels,
tendons, fibrous tissues, and connective tissue. It has been observed to be
capable of arising anywhere in the human body in a person of any age. Over 30
types of this cancer have been identified. The extent of this cancer’s
influence is also quite extensive, as the American Cancer Society estimates
that there are an additional 10,500 cases that are diagnosed in the U.S. each
year.
More
in-depth scientific information regarding aldoxorubicin and its cancer-ending
potential can be found at: www.cytrx.com/aldoxorubicin
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
